NasdaqCM:MDGS

Stock Analysis Report

Executive Summary

Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Medigus's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.6%

MDGS

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

-42.2%

MDGS

11.9%

US Medical Equipment

5.9%

US Market

Return vs Industry: MDGS underperformed the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: MDGS underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

MDGSIndustryMarket
7 Day-0.6%-0.003%1.3%
30 Day-11.2%-3.0%-1.9%
90 Day-22.9%-0.6%-1.8%
1 Year-42.2%-42.2%12.8%11.9%8.3%5.9%
3 Year-96.4%-96.4%69.6%64.5%45.6%36.2%
5 Yearn/a129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is Medigus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medigus undervalued compared to its fair value and its price relative to the market?

1.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate MDGS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate MDGS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDGS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MDGS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MDGS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDGS is good value based on its PB Ratio (1.1x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Medigus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Medigus performed over the past 5 years?

7.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MDGS is unprofitable, but has reduced losses over the past 5 years at a rate of 7% per year.

Accelerating Growth: Unable to compare MDGS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDGS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: MDGS has a negative Return on Equity (-95.84%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MDGS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MDGS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Medigus's financial position?


Financial Position Analysis

Short Term Liabilities: MDGS's short term assets ($9.6M) exceeds its short term liabilities ($1.6M)

Long Term Liabilities: MDGS's short term assets (9.6M) exceeds its long term liabilities (1.6M)


Debt to Equity History and Analysis

Debt Level: MDGS is debt free.

Reducing Debt: MDGS has not had any debt for past 5 years.


Balance Sheet

Inventory Level: MDGS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MDGS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDGS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MDGS has sufficient cash runway for 2.022771 years if free cash flow continues to grow at historical rates of 39.5% each year.


Next Steps

Dividend

What is Medigus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MDGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MDGS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MDGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDGS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDGS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Medigus's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Liron Carmel (34yo)

0.5yrs

Tenure

0

Mr. Liron Carmel has been Chief Executive Officer of Medigus Ltd. since April 1, 2019. Mr. Carmel served as Chief Executive Officer and Director of CannaPowder, Inc. since December 2014 until May 7, 219 an ...


Management Age and Tenure

0.6yrs

Average Tenure

36yo

Average Age

Experienced Management: MDGS's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Age and Tenure

1.1yrs

Average Tenure

49.5yo

Average Age

Experienced Board: MDGS's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Yaron Silberman (49yo)

    Chief Executive Officer of ScoutCam Ltd.

    • Tenure: 0.6yrs
    • Compensation: US$183.00k
  • Liron Carmel (34yo)

    Chief Executive Officer

    • Tenure: 0.5yrs
  • Ilan Oren

    Executive Officer

    • Tenure: 0yrs
    • Compensation: US$7.00k
  • Tatiana Yosef (36yo)

    Chief Financial Officer

    • Tenure: 0.6yrs

Board Members

  • Benad Goldwasser (69yo)

    Chairman of the board

    • Tenure: 1.1yrs
    • Compensation: US$37.12k
  • Eli Yoresh (49yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$37.12k
  • Ronen Rosenbloom (47yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$37.12k
  • Eli Cohen (50yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$37.12k
  • Kineret Tzedef

    Director

    • Tenure: 0.3yrs

Company Information

Medigus Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medigus Ltd.
  • Ticker: MDGS
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪23.919m
  • Listing Market Cap: ₪6.811m
  • Shares outstanding: 75.93m
  • Website: https://www.medigus.com

Number of Employees


Location

  • Medigus Ltd.
  • No. 7A, Omer Industrial Park
  • PO Box 3030
  • Omer
  • 8496500
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDGSTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSMar 2006
MDGSNasdaqCM (Nasdaq Capital Market)SPONSORED ADR 2018USUSDMay 2015
2QMBST (Boerse-Stuttgart)SPONSORED ADR 2018DEEURMay 2015

Biography

Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. I ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:37
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.